Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
This is a prospective, single-center, phase II study，to evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after resection.
Hepatocarcinoma
DRUG: Icariin Soft Capsules+TACE
Recurrence Free Survival Rate, The proportion of patients who did not experience recurrence or death, 12 months
Disease Free Survival, DFS defined as the time from date of treatment until the date of recurrence or death due to any cause, 24 months|Overall survival (OS), OS defined as the time from date of treatment until the date of death due to any cause, 24 months
This is a prospective, single-center, phase II study，to evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after resection.